China-based JW Therapeutics (HKG: 2126) has announced a carrier supply agreement with its shareholder Juno, aimed at supporting the continuous commercialization and further clinical development of its chimeric antigen receptor (CAR) T cell therapy, Carteyva (relmacabtagene autoleucel injection).
Financial Terms and Projections
The agreement outlines that from the effective date of the agreement to December 31, 2023, and for the subsequent two years ending December 31, 2024, and 2025, the total amount payable by JW Therapeutics to Juno under the carrier supply agreement is expected to not exceed approximately RMB 76.8 million, RMB 137.6 million, and RMB 220.1 million, respectively. These figures reflect the anticipated continuous uptake and manufacturing requirements for Carteyva following its commercialization.
Carteyva’s Approval and Market Performance
Relmacabtagene autoleucel, an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics, has been approved in China for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, and adult patients with follicular lymphoma that is refractory or has relapsed within 24 months of second-line or above systemic treatment (r/r FL). The drug’s sales in 2022 reached RMB 146 million (USD 20.8 million), a significant increase from RMB 30.8 million (USD 4.4 million) in 2021, indicating a strong market performance.-Fineline Info & Tech
